Pioneering GIP
receptor antagonism for obesity treatment

We’re addressing obesity and overweight through GIP receptor antagonism, developing treatments that go beyond weight loss to deliver long-term sustained health, without compromising on tolerability.

AT-7687

AT-7687 is Antag’s GIP receptor antagonist – a peptide drug designed not just as a stand-alone product but also as a flexible therapeutic agent that can be used in combination with existing anti-obesity medications and emergent treatments of obesity.

AT-7687 is engineered to target and deactivate the GIP receptor pathway, which, when dysregulated, contributes to fat storage, insulin resistance, and metabolic dysfunction.

Research to date has demonstrated several key benefits of AT-7687:

  • An excellent tolerability profile with no GI-related side effects and no need for titration, based on human data
  • Superior quality of weight loss with improvements across a range of biomarkers related to better cardiovascular outcomes and healthier body composition
  • Enabling additional weight loss in GLP-1 inadequate responders and patient populations with high sensitivity to the well-known gastrointestinal side effects of GLP-1s.
  • Straightforward and versatile formulation properties, uniquely positioned to develop AT-7687 as monotherapy or as co-formulation with GLP-1s and other emerging obesity medications (e.g., amylins) to address a broader range of patient needs and treatment scenarios